Prospective Open-label and Single-Center study for evaluation of efficacy and safety of Gutbio Capsule for Irritable Bowel Syndrome and its symptoms. - NI

Healing Hands &Herbs Pvt Ltd.0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年5月27日

研究概览

暂无简介。

•1.Patients aged 18 years & above.
•2.Patient with a diagnosis of irritable bowel syndrome.
•3.Patient or Parent or legal guardian willing to give a written informed consent or parental consent or assent form.
•4.Able to or Willing to strictly adhere to the investigator’s prescription.

•1.Individuals were excluded if they had taken any medications that might interfere with the action of the study medications prior to the start of the study or during the study.
•2.Subjects with a history of coeliac disease, Inflammatory Bowel disease, bowel cancer, bariatric surgery or surgical resection of the stomach, small intestine, or large intestine.
•3.Subjects with a history of unexplained weight loss or rectal bleeding.
•4.Female subjects who are pregnant or lactating or planning to become pregnant during the study period.
•5.Females who are not ready to use acceptable contraceptive methods during the course of study.

发起方

Healing Hands &Herbs Pvt Ltd.